Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity.

导出 OA

翻译打印收藏纠错

作者： Xian-Chun,Zhong ^[1] ; Ya-Meng,Liu ^[2] ; Xiao-Xia,Gao ^[2] ; Kristopher W,Krausz ^[3] ; Bing,Niu ^[3] ; Frank J,Gonzalez ^[1] ; Cen,Xie ^[4]

作者单位： School of Life Sciences, Shanghai University, Shanghai, 200444, China. ^[1] State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. ^[2] Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, 20892, Maryland, USA. ^[3] Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, 20892, Maryland, USA. gonzalef@mail.nih.gov. ^[4] State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. xiecen@simm.ac.cn. ^[5] Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, 20892, Maryland, USA. xiecen@simm.ac.cn. ^[6]

关键词 bile salt hydrolase caffeic acid phenethyl ester ceramide farnesoid X receptor gut microbiota nonalcoholic fatty liver disease